MA32233B1 - Régime de dosage pour un agoniste sélectif du récepteur s1p<sb>1</sb> - Google Patents
Régime de dosage pour un agoniste sélectif du récepteur s1p<sb>1</sb>Info
- Publication number
- MA32233B1 MA32233B1 MA33253A MA33253A MA32233B1 MA 32233 B1 MA32233 B1 MA 32233B1 MA 33253 A MA33253 A MA 33253A MA 33253 A MA33253 A MA 33253A MA 32233 B1 MA32233 B1 MA 32233B1
- Authority
- MA
- Morocco
- Prior art keywords
- selective
- dose
- receptor agonist
- receptor
- dosing system
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/425—Thiazoles
- A61K31/426—1,3-Thiazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/425—Thiazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/425—Thiazoles
- A61K31/427—Thiazoles not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/14—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/06—Antiarrhythmics
Abstract
La présente invention porte sur un régime de dosage pour un agoniste sélectif du récepteur s1p1, ce par quoi l'agoniste sélectif du récepteur s1p1 est administré à un sujet de telle sorte que, pendant la phase de traitement initiale, l'agoniste sélectif du récepteur s1p1 est administré à une dose qui induit une désensibilisation du c'ur, ladite dose étant inférieure à la dose cible, et à une fréquence de dosage qui entretient une désensibilisation du c'ur, jusqu'à ce qu'aucune autre réduction de la fréquence cardiaque aiguë ne se produise, en faisant suivre par une titration progressive avec augmentation de la dose jusqu'à la dose cible de l'agoniste sélectif du récepteur s1p1.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
IB2008050995 | 2008-03-17 | ||
PCT/IB2009/051030 WO2009115954A1 (fr) | 2008-03-17 | 2009-03-12 | Régime de dosage pour un agoniste sélectif du récepteur s1p<sb>1</sb> |
Publications (1)
Publication Number | Publication Date |
---|---|
MA32233B1 true MA32233B1 (fr) | 2011-04-01 |
Family
ID=40786618
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MA33253A MA32233B1 (fr) | 2008-03-17 | 2010-10-15 | Régime de dosage pour un agoniste sélectif du récepteur s1p<sb>1</sb> |
Country Status (27)
Country | Link |
---|---|
US (6) | US8785484B2 (fr) |
EP (1) | EP2278960B2 (fr) |
JP (2) | JP4846063B2 (fr) |
KR (3) | KR101718639B1 (fr) |
CN (2) | CN101980704A (fr) |
AR (1) | AR070842A1 (fr) |
AU (1) | AU2009227629B2 (fr) |
BR (1) | BRPI0909625B1 (fr) |
CA (1) | CA2716448A1 (fr) |
CY (1) | CY1118648T1 (fr) |
DK (1) | DK2278960T4 (fr) |
ES (1) | ES2617628T5 (fr) |
HR (1) | HRP20170246T4 (fr) |
HU (1) | HUE033168T2 (fr) |
IL (1) | IL208154A (fr) |
LT (1) | LT2278960T (fr) |
MA (1) | MA32233B1 (fr) |
MX (1) | MX2010009853A (fr) |
MY (1) | MY177360A (fr) |
NZ (1) | NZ588505A (fr) |
PL (1) | PL2278960T5 (fr) |
PT (1) | PT2278960T (fr) |
RU (1) | RU2519660C2 (fr) |
SI (1) | SI2278960T2 (fr) |
TW (1) | TWI434688B (fr) |
WO (1) | WO2009115954A1 (fr) |
ZA (1) | ZA201007367B (fr) |
Families Citing this family (26)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
USRE43833E1 (en) | 2003-11-21 | 2012-11-27 | Actelion Pharmaceuticals Ltd. | Thiazolidin-4-one derivatives |
DE602004029493D1 (de) | 2003-11-21 | 2010-11-18 | Actelion Pharmaceuticals Ltd | 5-(benz- (z) -yliden) -thiazolidin-4-onderivate als das immunsystem unterdrückende mittel |
DK2094676T3 (da) * | 2006-11-23 | 2013-06-10 | Actelion Pharmaceuticals Ltd | Ny fremgangsmåde til fremstillingen af 2-iminothiazolidin-4-on-derivater |
US8912340B2 (en) | 2006-11-23 | 2014-12-16 | Actelion Pharmaceuticals Ltd. | Process for the preparation of 2-imino-thiazolidin-4-one derivatives |
WO2009115954A1 (fr) | 2008-03-17 | 2009-09-24 | Actelion Pharmaceuticals Ltd | Régime de dosage pour un agoniste sélectif du récepteur s1p<sb>1</sb> |
GB0819182D0 (en) | 2008-10-20 | 2008-11-26 | Actelion Pharmaceuticals Ltd | Crystalline forms |
SI3409274T1 (sl) * | 2008-12-22 | 2020-03-31 | Novartis Ag | Režim odmerjanja za S1P receptor agonist |
ES2937386T3 (es) | 2010-01-27 | 2023-03-28 | Arena Pharm Inc | Procesos para la preparación de ácido (R)-2-(7-(4-ciclopentil-3-(trifluorometil)benciloxi)-1,2,3,4-tetrahidrociclopenta[b]indol-3-il)acético y sales del mismo |
CN102917698A (zh) * | 2010-05-06 | 2013-02-06 | 诺瓦提斯公司 | 二芳基硫醚衍生物的给药方案 |
PT2885266T (pt) | 2012-08-17 | 2020-05-29 | Actelion Pharmaceuticals Ltd | Processo para a preparação de (2z,5z)-5-(3-cloro-4-((r)-2,3-di-hidropropoxi)benzilideno)-2-(propilimino)-3-(o-tolil)tiazolidin-4-ona e intermediário utilizado no referido processo |
US20170165236A1 (en) | 2013-11-01 | 2017-06-15 | Celgene International Ii Sàrl | Selective sphingosine 1 phosphate receptor modulators and combination therapy therewith |
MA41139A (fr) | 2014-12-11 | 2017-10-17 | Actelion Pharmaceuticals Ltd | Combinaison pharmaceutique comportant un agoniste sélectif du récepteur sip1 |
AU2015359346B2 (en) | 2014-12-11 | 2020-05-07 | Actelion Pharmaceuticals Ltd | Dosing regimen for a selective S1P1 receptor agonist |
EP3242666A1 (fr) * | 2015-01-06 | 2017-11-15 | Arena Pharmaceuticals, Inc. | Procédés de traitement de maladies associées au récepteur s1p1 |
US20180042895A1 (en) | 2015-02-26 | 2018-02-15 | Novartis Ag | Treatment of autoimmune disease in a patient receiving additionally a beta-blocker |
JP6838744B2 (ja) | 2015-06-22 | 2021-03-03 | アリーナ ファーマシューティカルズ, インコーポレイテッド | S1P1レセプター関連障害における使用のための(R)−2−(7−(4−シクロペンチル−3−(トリフルオロメチル)ベンジルオキシ)−1,2,3,4−テトラヒドロシクロペンタ[b]インドール−3−イル)酢酸(化合物1)の結晶性L−アルギニン塩 |
KR20190116416A (ko) | 2017-02-16 | 2019-10-14 | 아레나 파마슈티칼스, 인크. | 원발 담즙성 담관염을 치료하기 위한 화합물 및 방법 |
CN110545848A (zh) * | 2017-02-16 | 2019-12-06 | 艾尼纳制药公司 | 用于治疗具有肠外表现的炎症性肠病的化合物和方法 |
JOP20190207A1 (ar) | 2017-03-14 | 2019-09-10 | Actelion Pharmaceuticals Ltd | تركيبة صيدلانية تشتمل على بونيسيمود |
US11014897B1 (en) | 2018-10-16 | 2021-05-25 | Celgene Corporation | Solid forms comprising a thiazolidinone compound, compositions and methods of use thereof |
US11013723B1 (en) | 2018-10-16 | 2021-05-25 | Celgene Corporation | Solid forms of a thiazolidinone compound, compositions and methods of use thereof |
US11014940B1 (en) | 2018-10-16 | 2021-05-25 | Celgene Corporation | Thiazolidinone and oxazolidinone compounds and formulations |
US11186556B1 (en) | 2018-10-16 | 2021-11-30 | Celgene Corporation | Salts of a thiazolidinone compound, solid forms, compositions and methods of use thereof |
CA3156298A1 (fr) | 2019-10-31 | 2021-05-06 | Laetitia POUZOL | Combinaison d'un antagoniste de cxcr7 avec un modulateur du recepteur s1p1 |
US11951097B2 (en) | 2021-10-11 | 2024-04-09 | Vanda Pharmaceuticals Inc. | Methods of treating multiple sclerosis |
EP4212156A1 (fr) | 2022-01-13 | 2023-07-19 | Abivax | Combinaison de 8-chloro-n-(4-(trifluorométhoxy)phényl)quinolin-2-amine et de ses dérivés avec un modulateur de récepteur de s1p |
Family Cites Families (54)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR0155015B1 (ko) | 1992-10-21 | 1998-12-01 | 고우야 마사시 | 2-아미노-1,3-프로판디올 화합물 및 면역 억제제 |
ATE279185T1 (de) | 1995-12-28 | 2004-10-15 | Mitsubishi Pharma Corp | 2-amino-2-(2-(4-octylphenyl)ethyl)propan-1,3-di l enthaltendes arzneimittel zur topischen anwendung zur behandlung von erkrankungen die durch eine störung des immunsystems hervorgerufen werden |
US6476004B1 (en) | 1996-07-18 | 2002-11-05 | Mitsubishi Pharma Corporation | Pharmaceutical composition |
JPH11209277A (ja) * | 1998-01-19 | 1999-08-03 | Yoshitomi Pharmaceut Ind Ltd | 医薬組成物 |
EP0990440B1 (fr) | 1997-02-27 | 2008-10-29 | Novartis AG | Composition pharmaceutique comprenant le 2-amino-2-[2-(4-octylphényl)éthyl]propane-1,3-diol, une lécithine et un saccharide |
EP1012150A4 (fr) | 1997-05-19 | 2002-05-29 | Sugen Inc | Composes d'heteroarylcarboxamide actifs contre les etats pathologiques lies aux proteine tyrosine kinases |
JPH1180026A (ja) | 1997-09-02 | 1999-03-23 | Yoshitomi Pharmaceut Ind Ltd | 新規免疫抑制剤、その使用方法およびその同定方法 |
WO2002012545A2 (fr) * | 2000-08-03 | 2002-02-14 | Cytovia, Inc. | Procédé d'identification d'agents immunosuppresseurs |
ATE507839T1 (de) | 2001-04-02 | 2011-05-15 | Genentech Inc | Kombinationstherapie |
PL365330A1 (en) | 2001-04-02 | 2004-12-27 | Astrazeneca Ab | Solid pharmaceutical composition comprising 4 -cyano-trifluoro-3-(4-fluorophenylsulphonyl)-2-hydroxy-2-methylpropiono- m toluidide and pvp |
US6495025B2 (en) | 2001-04-20 | 2002-12-17 | Aerovironment, Inc. | Electrochemical oxygen generator and process |
WO2002092018A2 (fr) * | 2001-05-16 | 2002-11-21 | Plotnikoff Nicholas P | Procedes destines a induire une reponse immunitaire soutenue |
CN1524002A (zh) | 2001-06-08 | 2004-08-25 | ��˹��ŵ�� | 治疗或预防产胰岛素细胞的移植排斥反应 |
MXPA04002679A (es) | 2001-09-27 | 2004-07-30 | Kyorin Seiyaku Kk | Derivados de sulfuro de diarilo, sales de los mismos y agentes inmunosupresores que utilizan los mismos. |
JP4152884B2 (ja) | 2001-09-27 | 2008-09-17 | 杏林製薬株式会社 | ジアリールエーテル誘導体とその付加塩及び免疫抑制剤 |
US7479504B2 (en) | 2002-01-18 | 2009-01-20 | Merck & Co., Inc. | Edg receptor agonists |
EP1469863A2 (fr) | 2002-01-18 | 2004-10-27 | Merck & Co., Inc. | Antagonisteses lectifs du recepteur s1p1/edg1 |
GB0217152D0 (en) * | 2002-07-24 | 2002-09-04 | Novartis Ag | Organic compounds |
KR20080103117A (ko) | 2002-09-24 | 2008-11-26 | 노파르티스 아게 | 탈수초성 장애의 치료에 있어서의 스핑고신-1-포스페이트 수용체 아고니스트 |
HUE028247T2 (en) | 2003-04-08 | 2016-12-28 | Novartis Ag | A solid oral composition comprising S1P receptor agonist and sugar alcohol |
MY150088A (en) | 2003-05-19 | 2013-11-29 | Irm Llc | Immunosuppressant compounds and compositions |
DE602004029493D1 (de) | 2003-11-21 | 2010-11-18 | Actelion Pharmaceuticals Ltd | 5-(benz- (z) -yliden) -thiazolidin-4-onderivate als das immunsystem unterdrückende mittel |
USRE43833E1 (en) | 2003-11-21 | 2012-11-27 | Actelion Pharmaceuticals Ltd. | Thiazolidin-4-one derivatives |
WO2005123677A1 (fr) | 2004-06-16 | 2005-12-29 | Actelion Pharmaceuticals Ltd | Utilisation de derives de 1,1,2-trimethyl-1a,4,5,5a-tetrahydro-1h-4-aza-cyclopropa[a]pentalene a substitution 4-carbonyle comme agonistes du recepteur couple aux proteines g s1p1/edg1 et agents immunosuppresseurs |
WO2006010379A1 (fr) | 2004-07-29 | 2006-02-02 | Actelion Pharmaceuticals Ltd. | Nouveaux derives du thiophene utilises comme agents immunosupresseurs |
WO2006041015A1 (fr) | 2004-10-12 | 2006-04-20 | Kyorin Pharmaceutical Co., Ltd. | Dérivé d’aminoalcool, sel d’addition dudit dérivé, et agent immunosuppresseur |
US20060090658A1 (en) * | 2004-11-01 | 2006-05-04 | Michael Phillips | Tissue marking system |
JP2008521827A (ja) * | 2004-11-29 | 2008-06-26 | ノバルティス アクチエンゲゼルシャフト | S1p受容体アゴニストの投与レジメン |
JP5047941B2 (ja) | 2005-03-23 | 2012-10-10 | アクテリオン ファーマシューティカルズ リミテッド | 免疫調節物質としての水素付加されたベンゾ(c)チオフェン誘導体 |
RU2404178C2 (ru) | 2005-03-23 | 2010-11-20 | Актелион Фармасьютиклз Лтд | Новые производные тиофена в качестве агонистов рецептора сфингозин-1-фосфата-1 |
CN101180050B (zh) | 2005-03-23 | 2011-07-27 | 埃科特莱茵药品有限公司 | 作为鞘氨醇-1-磷酸盐-1受体激动剂的新颖噻吩衍生物 |
AU2006260573A1 (en) | 2005-06-24 | 2006-12-28 | Actelion Pharmaceuticals Ltd. | Novel thiophene derivatives |
AR057894A1 (es) | 2005-11-23 | 2007-12-26 | Actelion Pharmaceuticals Ltd | Derivados de tiofeno |
TWI404706B (zh) | 2006-01-11 | 2013-08-11 | Actelion Pharmaceuticals Ltd | 新穎噻吩衍生物 |
EP1979345B1 (fr) | 2006-01-24 | 2009-11-04 | Actelion Pharmaceuticals Ltd. | Nouveaux dérivés de pyridine |
US7879821B2 (en) * | 2006-01-26 | 2011-02-01 | University Of Medicine And Dentistry Of New Jersey | Method for modulating inflammatory responses by altering plasma lipid levels |
AR061841A1 (es) | 2006-09-07 | 2008-09-24 | Actelion Pharmaceuticals Ltd | Derivados de tiofen-oxadiazoles, agonistas del receptor s1p1/edg1, composiciones farmaceuticas que los contienen y usos como agentes inmunomoduladores. |
AU2007292993B2 (en) | 2006-09-07 | 2013-01-24 | Idorsia Pharmaceuticals Ltd | Pyridin-4-yl derivatives as immunomodulating agents |
CA2661315C (fr) | 2006-09-08 | 2015-11-24 | Actelion Pharmaceuticals Ltd | Derives de pyridin-3-yle en tant qu'agents immunomodulateurs |
RU2442780C2 (ru) | 2006-09-21 | 2012-02-20 | Актелион Фармасьютиклз Лтд | Фенильные производные и их применение в качестве иммуномодуляторов |
DK2094676T3 (da) | 2006-11-23 | 2013-06-10 | Actelion Pharmaceuticals Ltd | Ny fremgangsmåde til fremstillingen af 2-iminothiazolidin-4-on-derivater |
US8912340B2 (en) | 2006-11-23 | 2014-12-16 | Actelion Pharmaceuticals Ltd. | Process for the preparation of 2-imino-thiazolidin-4-one derivatives |
DK2125797T3 (da) | 2007-03-16 | 2014-02-10 | Actelion Pharmaceuticals Ltd | Aminopyridinderivater som s1p1/edg1-receptoragonister |
SI2195311T1 (sl) | 2007-08-17 | 2011-07-29 | Actelion Pharmaceuticals Ltd | Derivati piridina kot modulatorji receptorja s1p1/edg1 |
WO2009048993A2 (fr) | 2007-10-12 | 2009-04-16 | Novartis Ag | Compositions comprenant des modulateurs du récepteur de sphingosine 1-phosphate (s1p) |
WO2009115954A1 (fr) | 2008-03-17 | 2009-09-24 | Actelion Pharmaceuticals Ltd | Régime de dosage pour un agoniste sélectif du récepteur s1p<sb>1</sb> |
SI2342205T1 (sl) * | 2008-08-27 | 2016-09-30 | Arena Pharmaceuticals, Inc. | Substituirani triciklični kislinski derivati kot agonisti S1P1 receptorja, uporabni v zdravljenju avtoimunskih in vnetnih obolenj |
GB0819182D0 (en) | 2008-10-20 | 2008-11-26 | Actelion Pharmaceuticals Ltd | Crystalline forms |
PL2379069T3 (pl) | 2008-12-22 | 2015-08-31 | Novartis Ag | Schemat dawkowania agonisty receptora S1P |
SI3409274T1 (sl) | 2008-12-22 | 2020-03-31 | Novartis Ag | Režim odmerjanja za S1P receptor agonist |
JP5416600B2 (ja) | 2010-01-22 | 2014-02-12 | 株式会社日立ハイテクノロジーズ | 欠陥検査装置およびその方法 |
PT2885266T (pt) | 2012-08-17 | 2020-05-29 | Actelion Pharmaceuticals Ltd | Processo para a preparação de (2z,5z)-5-(3-cloro-4-((r)-2,3-di-hidropropoxi)benzilideno)-2-(propilimino)-3-(o-tolil)tiazolidin-4-ona e intermediário utilizado no referido processo |
MA41139A (fr) | 2014-12-11 | 2017-10-17 | Actelion Pharmaceuticals Ltd | Combinaison pharmaceutique comportant un agoniste sélectif du récepteur sip1 |
AU2015359346B2 (en) | 2014-12-11 | 2020-05-07 | Actelion Pharmaceuticals Ltd | Dosing regimen for a selective S1P1 receptor agonist |
-
2009
- 2009-03-12 WO PCT/IB2009/051030 patent/WO2009115954A1/fr active Application Filing
- 2009-03-12 PL PL09721703T patent/PL2278960T5/pl unknown
- 2009-03-12 JP JP2011500324A patent/JP4846063B2/ja active Active
- 2009-03-12 KR KR1020157002281A patent/KR101718639B1/ko active IP Right Grant
- 2009-03-12 SI SI200931616T patent/SI2278960T2/sl unknown
- 2009-03-12 NZ NZ588505A patent/NZ588505A/xx unknown
- 2009-03-12 RU RU2010141579/15A patent/RU2519660C2/ru active
- 2009-03-12 EP EP09721703.8A patent/EP2278960B2/fr active Active
- 2009-03-12 CA CA2716448A patent/CA2716448A1/fr not_active Abandoned
- 2009-03-12 CN CN2009801101149A patent/CN101980704A/zh active Pending
- 2009-03-12 CN CN201510090161.9A patent/CN104800208A/zh active Pending
- 2009-03-12 US US12/922,777 patent/US8785484B2/en active Active
- 2009-03-12 HU HUE09721703A patent/HUE033168T2/en unknown
- 2009-03-12 LT LTEP09721703.8T patent/LT2278960T/lt unknown
- 2009-03-12 KR KR1020107022801A patent/KR20100134032A/ko active IP Right Grant
- 2009-03-12 MY MYPI2010004328A patent/MY177360A/en unknown
- 2009-03-12 AU AU2009227629A patent/AU2009227629B2/en active Active
- 2009-03-12 ES ES09721703T patent/ES2617628T5/es active Active
- 2009-03-12 MX MX2010009853A patent/MX2010009853A/es active IP Right Grant
- 2009-03-12 DK DK09721703.8T patent/DK2278960T4/da active
- 2009-03-12 AR ARP090100886A patent/AR070842A1/es unknown
- 2009-03-12 KR KR1020147005406A patent/KR101653071B1/ko active IP Right Grant
- 2009-03-12 PT PT97217038T patent/PT2278960T/pt unknown
- 2009-03-12 BR BRPI0909625-6A patent/BRPI0909625B1/pt active IP Right Grant
- 2009-03-16 TW TW098108497A patent/TWI434688B/zh active
-
2010
- 2010-09-15 IL IL208154A patent/IL208154A/en active IP Right Grant
- 2010-10-14 ZA ZA2010/07367A patent/ZA201007367B/en unknown
- 2010-10-15 MA MA33253A patent/MA32233B1/fr unknown
-
2011
- 2011-08-30 JP JP2011186874A patent/JP4938905B2/ja active Active
-
2014
- 2014-06-18 US US14/308,598 patent/US20140303217A1/en not_active Abandoned
- 2014-07-02 US US14/322,801 patent/US20140315964A1/en not_active Abandoned
- 2014-07-02 US US14/322,722 patent/US10660880B2/en active Active
-
2015
- 2015-06-05 US US14/732,013 patent/US10251867B2/en active Active
-
2017
- 2017-02-02 CY CY20171100154T patent/CY1118648T1/el unknown
- 2017-02-15 HR HRP20170246TT patent/HRP20170246T4/hr unknown
-
2021
- 2021-09-09 US US17/470,905 patent/US20210401811A1/en not_active Abandoned
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
MA32233B1 (fr) | Régime de dosage pour un agoniste sélectif du récepteur s1p<sb>1</sb> | |
Gajraj | Pregabalin: its pharmacology and use in pain management | |
MA31396B1 (fr) | Therapie de combinaison avec un compose agissant comme inhibiteur de recepteur a l'adp de plaquettes | |
EA201001253A1 (ru) | N,n-дизамещенные аминоалкилбифенилы в качестве антагонистов рецепторов простагландина d | |
Frånberg et al. | Involvement of 5‐HT2A receptor and α2‐adrenoceptor blockade in the asenapine‐induced elevation of prefrontal cortical monoamine outflow | |
O’Connor et al. | The effects of mGlu7 receptor modulation in behavioural models sensitive to antidepressant action in two mouse strains | |
CL2017001479A1 (es) | Combinación farmacéutica que comprende un agonista selectivo del receptor s1p1 | |
RU2019143573A (ru) | Комбинированная терапия нейропсихиатрических расстройств, восприимчивых к антагонисту nmdar | |
CU20210099A7 (es) | Anticuerpos de receptor de péptido natriurético 1 | |
Casolla et al. | Treatment of perimenstrual migraine with triptans: an update | |
Isiordia‐Espinoza et al. | Synergism between tramadol and meloxicam in the formalin test involves both opioidergic and serotonergic pathways | |
Srejovic et al. | Modulation of N-methyl-d-aspartate receptors in isolated rat heart | |
EP4233850A3 (fr) | Formulations de capsules | |
El Desoky | The AMPA receptor antagonist perampanel is a new hope in the treatment for epilepsy | |
EA201692424A1 (ru) | Комбинации локсопрофена и агониста рецепторов гамма-аминомасляной кислоты | |
Korkmaz et al. | Extracellular signal-regulated kinase (ERK1/2) contributes to endotoxin-induced hyporeactivity via nitric oxide and prostacyclin production in rat aorta | |
Ren et al. | Research Progress of the Antidepressants Targeting the Monomine Receptors and Glutamate System | |
Guilliams | Hypotension, oliguria and lactic acidosis in a child: case report | |
Ibraimi et al. | NON-STEROIDAL ANTI-INFLAMMATORY DRUGS AND RENAL DISEASES. | |
Kutlug | Acute generalised exanthematous pustulosis: case report | |
Ramirez | Neuropathic pain and mild diarrhoea: case report | |
MA38310B2 (fr) | Combinaison médicamenteuse comprenant la phényléphrine et le paracétamol | |
Bellesoeur | Various toxicities: case report | |
Sharma | Amfetamine mixed salts/alcohol interaction | |
Sprenger | Migraine with aura: case report |